Table 3 Methodological quality of randomised controlled trials
Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No of Participants (studies) | Quality of the evidence (GRADE)†| |
|---|---|---|---|---|---|
Assumed risk (per 1000) | orresponding risk (per 1000) | ||||
Adefovir | Tenofovir | ||||
HBV-DNA suppression | 425 | 1000(429 to 1000) | RR 2.59 (1.01 to 6.67) | 694(3 studies) | low⊕⊕▯▯ |
   HBV-HIV coinfected subgroup | 185 | 440(248 to 784) | RR 2.38 (1.34 to 4.24) | 137(2 studies) | moderate⊕⊕⊕▯ |
ALT normalization | 634 | 729(609 to 869) | RR 1.15 (0.96 to 1.37) | 768(5 studies) | low⊕⊕▯▯ |
   lamivudine-resistance subgroup | 554 | 731(554 to 964) | RR 1.32 (1.00 to 1.74) | 132(2 studies) | low⊕⊕▯▯ |
HBeAg seroconversion | 140 | 167(104 to 267) | RR 1.19 (0.74 to 1.91) | 387(3 studies) | low⊕⊕▯▯ |
HBsAg loss | 0 | 0 | RR 5.74 (0.32 to 102.59) | 615(2 studies) | high⊕⊕⊕⊕ |